Status:
UNKNOWN
Catumaxomab in Patients With Non-Muscle-Invasive Bladder Cancer Who Have Failed or Are Intolerant to BCG Vaccine
Lead Sponsor:
LintonPharm Co.,Ltd.
Conditions:
Bladder Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
A Multicenter, Non-randomized, Uncontrolled, Open-label Phase I/II study to Observe the Safety and Preliminary Efficacy of Catumaxomab in Patients with Non-Muscle-Invasive Bladder Cancer who have Fail...
Detailed Description
This is a multicenter, non-randomized, uncontrolled, open-label phase I/II study to observe the safety and preliminary efficiency of catumaxomab in patients (hereinafter referred to as participants) w...
Eligibility Criteria
Inclusion
- Signed and dated informed consent forms have been provided.
- Willing to be complaint with the study procedures during the study.
- Male or female, age ≥ 18 years old when signing informed consents.
- Histologically or cytologically diagnosed as NMIBC, i.e., bladder cancer in the following pTNM status: pTis, pTa, pT1.
- Have received the standard therapy recommended in the current NMIBC clinical guidelines, including intravesical BCG instillation, and diagnosed as BCG failure or intolerance.
- Participants had completed TURBT or cystoscopy as required by guidelines prior to enrollment, and no significant tumours were seen in the surgical field Residual lesions
- Recovered from any toxicity due to previous treatment (Grade 0-1 according to NCI-CTCAE v 5.0).
- Estimated life span is ≥ 6 months.
- Eastern Oncology Cooperative Group (ECOG) performance status 0-1.
- The laboratory test values during the screening period are in accordance with the following table:
- ANC(absolute neutrophil count)\>=1.5x10\^9/L
- Hemoglobin\>=80 g/L
- Platelet\>=100x10\^9/L
- Lymphocyte percentage\>=20%
- Serum Bilirubin \<=1.25
- ULN(or 2.5 ULN if there is Gilbert)
- AST and ALT \<=2.5 ULN without liver metastasis（or\<=5 ULN if liver metastasis)
- Serum creatinine \<=2.0 mg/dL or
- Calculated creatinine clearance\>=30 mL/min.
- For women of childbearing potential: use an efficient method for contraception at least 1 month prior to screening and agree to use this method for contraception during the study period and 30 days after the last intravesical instillation.;
- For men with fertility potential: use condoms or other methods to ensure effective contraception for sexual partners from screening to 30 days after the last intravesical instillation.
Exclusion
- Known or suspected of being allergic to catumaxomab or similar antibodies.
- Besides the TURBT + immediate postoperative infusion chemotherapy for this NMIBC recurrence, participants received other anti-tumor treatments, including other anti-tumor investigational drugs, chemotherapy, immunotherapy, biological agents, hormone therapy, radiation therapy (excluding local radiation therapy for pain relief), etc., the interval between the last instillation and the first intravesical instillation is ≤ 21 days.
- Tumor metastases outside the bladder confirmed in imaging examination.
- With other primary malignant tumors diagnosed before the signing of ICF, excluding squamous cell carcinoma in situ of skin or cervical carcinoma in situ without recurrence within 5 years after resection.
- The following diseases have not been resolved to CTCAE grade 0-1 in 3 days prior to the first instillation:
- Uncontrolled acute and chronic infections such as pneumonia, biliary infection, hepatitis B virus infection and hepatitis C virus infection, etc.
- Dyspnea.
- Acute /chronic renal injury.
- Nephrotic syndrome.
- Bladder perforation.
- Urinary tract obstruction(except benign prostatic hypertrophy).
- NYHA Class 3 or 4.
- Related symptoms and signs of cardiovascular diseases have not been resolved to CTCAE grade 0-1: including myocardial infarction, congestive heart failure, and arrhythmia.
- Known cerebrovascular accidents have not been resolved to CTCAE grade 0-1.
- History of autoimmune diseases (eg, inflammatory bowel disease, idiopathic thrombocytopenic purpura, systemic lupus erythematosus, autologous hemolytic anemia, rheumatoid arthritis, etc.).
- Patients with known HIV serology positive, hepatitis C infection and/or hepatitis B (Except the patients with positive HepBsAg or core antibody are responding to anti-HBV treatment, they are allowed to participate in the study.
- Notes: HepBsAg-negative patients at screening, or patients are undergoing treatment with interferon-2a \[IFN\] or peginterferon-2a \[Peg-IFN\] and hepatitis B virus \[HBV\] DNA \< 2000 international units \[IU\], or partients who are receiving nucleoside \[acid\] analogues at screening and HBV DNA below the lower limit of normal \[LLN\] are eligible to participate in the study.
- Pregnancy or breastfeeding during study treatment and follow-up period.
- Patients with confirmed past history of neurological or psychotic disorders, including epilepsy or dementia.
- Other serious systemic conditions that may limit the participation in this study (e.g. uncontrolled diabetes, cardiovascular and cerebrovascular disease, severe gastrointestinal disease, and renal disease, etc.).
Key Trial Info
Start Date :
November 23 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 30 2024
Estimated Enrollment :
161 Patients enrolled
Trial Details
Trial ID
NCT04799847
Start Date
November 23 2021
End Date
November 30 2024
Last Update
February 13 2023
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital,Sun Yat-sen University
Guangzhou, Guangdong, China, 510080
2
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China
3
Peking University Third Hospital
Beijing, China
4
Sun Yat-sen University Cancer Center
Guangzhou, China